Obstructive Sleep Apnea - Pipeline Review, H2 2016

Global Markets Direct’s, ‘Obstructive Sleep Apnea - Pipeline Review, H2 2016’, provides an overview of the Obstructive Sleep Apnea pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Obstructive Sleep Apnea, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Obstructive Sleep Apnea and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Obstructive Sleep Apnea

The report reviews pipeline therapeutics for Obstructive Sleep Apnea by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Obstructive Sleep Apnea therapeutics and enlists all their major and minor projects

The report assesses Obstructive Sleep Apnea therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Obstructive Sleep Apnea

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Obstructive Sleep Apnea

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Obstructive Sleep Apnea pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Galleon Pharmaceuticals Inc

RespireRx Pharmaceuticals Inc

SK Biopharmaceuticals Co Ltd

Vivus Inc

Galleon Pharmaceuticals Inc

RespireRx Pharmaceuticals Inc

SK Biopharmaceuticals Co Ltd

Vivus Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Obstructive Sleep ...

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Obstructive Sleep Apnea Overview 6

Therapeutics Development 7

Pipeline Products for Obstructive Sleep Apnea - Overview 7

Obstructive Sleep Apnea - Therapeutics under Development by Companies 8

Obstructive Sleep Apnea - Pipeline Products Glance 9

Late Stage Products 9

Clinical Stage Products 10

Early Stage Products 11

Obstructive Sleep Apnea - Products under Development by Companies 12

Obstructive Sleep Apnea - Companies Involved in Therapeutics Development 13

Galleon Pharmaceuticals Inc 13

RespireRx Pharmaceuticals Inc 14

SK Biopharmaceuticals Co Ltd 15

Vivus Inc 16

Obstructive Sleep Apnea - Therapeutics Assessment 17

Assessment by Monotherapy Products 17

Assessment by Combination Products 18

Assessment by Target 19

Assessment by Mechanism of Action 21

Assessment by Route of Administration 23

Assessment by Molecule Type 24

Drug Profiles 25

(phentermine + topiramate) ER - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

dronabinol - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

GAL-475 - Drug Profile 33

Product Description 33

Mechanism Of Action 33

R&D Progress 33

GAL-475 Backups - Drug Profile 34

Product Description 34

Mechanism Of Action 34

R&D Progress 34

SKL-N05 - Drug Profile 35

Product Description 35

Mechanism Of Action 35

R&D Progress 35

Obstructive Sleep Apnea - Dormant Projects 38

Obstructive Sleep Apnea - Discontinued Products 39

Obstructive Sleep Apnea - Product Development Milestones 40

Featured News & Press Releases 40

Sep 26, 2016: Jazz Pharmaceuticals Announces That Patient Enrollment is Complete for the Phase 3 Studies of JZP-110 Evaluating Excessive Sleepiness in Obstructive Sleep Apnea 40

Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting 40

Jun 08, 2015: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Clinical Development Program Evaluating JZP-110 as a Potential Treatment of EDS Associated with Narcolepsy or with OSA 41

May 14, 2015: VIVUS Announces Scientific Presentations 42

May 15, 2014: VIVUS Announces Qsymia Presentation at the American Association of Clinical Endocrinologists 43

Jul 01, 2013: VIVUS Announces Initial Availability of Qsymia Through Certified Retail Pharmacies 43

Nov 12, 2012: Study Finds Significant Improvements In Patients With Obstructive Sleep Apnea Treated With Phentermine And Topiramate Extended-Release Capsules 44

Jan 09, 2012: VIVUS Provides Update On Regulatory Status Of Qnexa 45

Nov 03, 2011: FDA Accepts New Drug Application Filing For Qnexa 46

Jan 07, 2010: VIVUS Announces Positive Results From Phase II Study Of Qnexa In Obstructive Sleep Apnea 46

Appendix 48

Methodology 48

Coverage 48

Secondary Research 48

Primary Research 48

Expert Panel Validation 48

Contact Us 48

Disclaimer 49

List of Tables

List of Tables

Number of Products under Development for Obstructive Sleep Apnea, H2 2016 7

Number of Products under Development by Companies, H2 2016 8 ...

List of Tables

Number of Products under Development for Obstructive Sleep Apnea, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Clinical Stage Development, H2 2016 10

Comparative Analysis by Early Stage Development, H2 2016 11

Products under Development by Companies, H2 2016 12

Obstructive Sleep Apnea - Pipeline by Galleon Pharmaceuticals Inc, H2 2016 13

Obstructive Sleep Apnea - Pipeline by RespireRx Pharmaceuticals Inc, H2 2016 14

Obstructive Sleep Apnea - Pipeline by SK Biopharmaceuticals Co Ltd, H2 2016 15

Obstructive Sleep Apnea - Pipeline by Vivus Inc, H2 2016 16

Assessment by Monotherapy Products, H2 2016 17

Assessment by Combination Products, H2 2016 18

Number of Products by Stage and Target, H2 2016 20

Number of Products by Stage and Mechanism of Action, H2 2016 22

Number of Products by Stage and Route of Administration, H2 2016 23

Number of Products by Stage and Molecule Type, H2 2016 24

Obstructive Sleep Apnea - Dormant Projects, H2 2016 38

Obstructive Sleep Apnea - Discontinued Products, H2 2016 39

List of Figures

List of Figures

Number of Products under Development for Obstructive Sleep Apnea, H2 2016 7

Number of Products under Development by Companies, H2 2016 8 ...

List of Figures

Number of Products under Development for Obstructive Sleep Apnea, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Assessment by Monotherapy Products, H2 2016 17

Number of Products by Top 10 Targets, H2 2016 19

Number of Products by Stage and Top 10 Targets, H2 2016 19

Number of Products by Top 10 Mechanism of Actions, H2 2016 21

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 21

Number of Products by Stage and Routes of Administration, H2 2016 23

Number of Products by Stage and Molecule Types, H2 2016 24

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports